CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Research Seminars New Drugs for COPD: the current status

2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD

Despite remarkable progresses in the definition of cellular, biochemical and molecular biology pathways in the pathogenesis of Severe Asthma, Chronic Obstructive Pulmonary Disorder (COPD) and Interstitial Lung Disorders (ILDs), there is still a substantial unmet need for new drugs able to control and/or change the natural history of these diseases. This Seminar intended to underline the key role of a side-to-side collaboration between clinicians, scientists, bioinformaticians and statisticians in the comprehension of pathological processes underlying different respiratory disorders. It provided a framework to improve the ability to identify potential pharmacological targets for the development of innovative drugs.

New Drugs for COPD: the current status

Speaker(s): I. Adcock (London, United Kingdom)

BACK TO EVENT

Limited Access

Please log in to myERS to view this content.

Don't have a myERS account? Register

Note: consult the ERS Respiratory Channel access rights page for more details.

2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD

Limited Access

#{title}